Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + GEMOX in advanced biliary tract cancer
NCT03486678Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2018
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in biliary tract cancer (BTC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: 6-month Progression Free Survival rate and Incidence of Treatment-Emergent Adverse Events. Started Feb 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03486678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486678.